Union européenne - suédois - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiska medel - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Union européenne - suédois - EMA (European Medicines Agency)

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - calciumhomeostas - behandling av osteoporos hos postmenopausala kvinnor med ökad risk för fraktur.

Union européenne - suédois - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Union européenne - suédois - EMA (European Medicines Agency)

proveca pharma limited - enalapril (maleate) - hjärtsvikt - agenter som verkar på renin-angiotensinsystemet - treatment of heart failure.

Suède - suédois - Läkemedelsverket (Medical Products Agency)

navamedic asa - ceftriaxonnatrium (hemiheptahydrat) - pulver till injektions-/infusionsvätska, lösning - 1 g - ceftriaxonnatrium (hemiheptahydrat) 1,193 g aktiv substans - ceftriaxon

Suède - suédois - Läkemedelsverket (Medical Products Agency)

navamedic asa - ceftriaxonnatrium (hemiheptahydrat) - pulver till infusionsvätska, lösning - 2 g - ceftriaxonnatrium (hemiheptahydrat) 2,386 g aktiv substans - ceftriaxon

Suède - suédois - Läkemedelsverket (Medical Products Agency)

xellia pharmaceuticals aps - vankomycinhydroklorid - pulver till infusionsvätska, lösning - 1 g - vankomycinhydroklorid 1,026 g aktiv substans - vankomycin

Suède - suédois - Läkemedelsverket (Medical Products Agency)

mip pharma gmbh - vankomycinhydroklorid - pulver till infusionsvätska, lösning - 1000 mg - vankomycinhydroklorid 1020 mg aktiv substans - vankomycin

Suède - suédois - Läkemedelsverket (Medical Products Agency)

mylan ire healthcare ltd - vankomycinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 1000 mg - vankomycinhydroklorid 1025,32 mg aktiv substans - vankomycin

Suède - suédois - Läkemedelsverket (Medical Products Agency)

orion corporation - vankomycinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 1000 mg - vankomycinhydroklorid 1025,14 mg aktiv substans - vankomycin